ESMO Breast 2022 | Evaluating the requirement for chemotherapy in patients with HR+ BC

Nadia Harbeck, MD, PhD, Ludwig Maximilians University – Grosshadern, Munich, Germany, talks on the Phase II ADAPT (NCT01817452) clinical trial data, in regard to endocrine response testing. 5000 woman with HR-positive and node-positive or node-negative breast cancer received 4 weeks of endocrine therapy prior to surgery. Patients’ Ki-67 levels were assessed following treatment. A Ki-67 score of 10% or less being considered as an endocrine response. The Oncotype DX Breast Recurrence Score was additionally evaluated. If patients had an Oncotype DX score of 25 or less and an endocrine response, chemotherapy was withheld. The overall results showed the addition of assessing endocrine response aids in deciding to withhold patients from unnecessary chemotherapy more accurately than a genomic assay alone. This interview took place at the European Society for Medical Oncology (ESMO) Breast Cancer 2022 congress in Berlin, Germany.